Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer, Inc.    PFE

PFIZER, INC.

(PFE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/05/2020 08/06/2020 08/07/2020 08/10/2020 08/11/2020 Date
38.45(c) 38.27(c) 38.45(c) 38.39(c) 37.79(c) Last
23 344 231 19 850 154 21 913 899 18 941 735 20 172 036 Volume
+0.16% -0.47% +0.47% -0.16% -1.56% Change
More quotes
Financials (USD)
Sales 2020 48 800 M - -
Net income 2020 13 460 M - -
Net Debt 2020 32 571 M - -
P/E ratio 2020 17,9x
Yield 2020 4,01%
Sales 2021 53 420 M - -
Net income 2021 13 544 M - -
Net Debt 2021 11 302 M - -
P/E ratio 2021 15,5x
Yield 2021 4,18%
Capitalization 210 B 210 B -
EV / Sales 2020 4,97x
EV / Sales 2021 4,14x
Nbr of Employees 88 300
Free-Float 59,1%
More Financials
Company
Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows: - biopharmaceuticals (76.2%): innovative drugs for the treatment of cancer, inflammatory, autoimmune, infectious, metabolic, cardiovascular and rare diseases, vaccines, etc. In addition, the group develops an active pharmaceutical ingredient manufacturing activity; - generic pharmaceutical products (19.8%;... 
Sector
Pharmaceuticals
Calendar
09/14 | 01:00pmInvestor Day - Day 1
More about the company
Surperformance© ratings of Pfizer, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER, INC.
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
RE
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Gilead seeks U.S. approval for COVID-19 treatment remdesivir
RE
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
RE
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
RE
08/10PFIZER : Basilea reports acceptance for regulatory review of Pfizer's marketing ..
AQ
08/10PFIZER : Announces Agreement with Gilead to Manufacture Remdesivir for Treatment..
AQ
08/10PFIZER : Bioquebec - government of canada announces major steps in treating and ..
AQ
08/07Health Care Up Slightly As Investors Gauge Covid Treatment Odds - Health Care..
DJ
08/07Pfizer to Manufacture Gilead's Remdesivir for Covid-19 Treatment -- Update
DJ
08/07NEWS HIGHLIGHTS : Top Company News of the Day
DJ
08/07Pfizer to Manufacture Gilead's Remdesivir for Covid-19 Treatment
DJ
More news
News in other languages on PFIZER, INC.
09:21aDPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 11.08.2020 - 15.15 Uhr
08:13aBiontech peilt weiter Impfstoffzulassung im Oktober an - Quartalszahlen
08:09aVerlust von Biontech steigt - Covid-Impfstoffdaten für Oktober erwartet
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Stock Trading Strategies
PFIZER, INC. - 07/28
Increase of volatility
BUY
More Stock Trading Analysis
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 42,53 $
Last Close Price 37,79 $
Spread / Highest target 45,5%
Spread / Average Target 12,5%
Spread / Lowest Target -7,38%
EPS Revisions
Managers
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Wyllie Don Cornwell Independent Director
Suzanne Nora Johnson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.-2.02%213 329
JOHNSON & JOHNSON1.87%389 737
ROCHE HOLDING AG-0.11%293 027
MERCK & CO., INC.-11.04%204 641
NOVARTIS AG-17.86%181 730
ABBVIE INC.4.34%163 035